Mark S. Freedman mainly investigates Multiple sclerosis, Internal medicine, Surgery, Placebo and Expanded Disability Status Scale. His Multiple sclerosis research includes elements of Hematopoietic stem cell transplantation, Transplantation, MEDLINE, Pathology and Intensive care medicine. His Internal medicine research integrates issues from Gastroenterology and Teriflunomide.
His Surgery research incorporates elements of Nerve fiber layer, Ophthalmology, Optic nerve and Clinically isolated syndrome. His work carried out in the field of Placebo brings together such families of science as Siponimod and Adverse effect, Tolerability, Clinical trial, Intention-to-treat analysis. His Expanded Disability Status Scale study combines topics in areas such as Placebo-controlled study and Interferon beta-1b.
Mark S. Freedman mainly focuses on Multiple sclerosis, Internal medicine, In patient, Placebo and Surgery. His Multiple sclerosis study is concerned with the field of Immunology as a whole. He interconnects Gastroenterology, Teriflunomide, Expanded Disability Status Scale and Oncology in the investigation of issues within Internal medicine.
His Expanded Disability Status Scale research is multidisciplinary, incorporating elements of Physical therapy and Hazard ratio. His work investigates the relationship between Placebo and topics such as Clinically isolated syndrome that intersect with problems in Interferon beta-1b and McDonald criteria. Many of his studies on Surgery involve topics that are commonly interrelated, such as Interferon beta-1a.
His main research concerns Multiple sclerosis, Internal medicine, In patient, Teriflunomide and Placebo. His Multiple sclerosis study integrates concerns from other disciplines, such as Hematopoietic stem cell transplantation, Disease, Clinical trial, Disability progression and Neurology. The concepts of his Hematopoietic stem cell transplantation study are interwoven with issues in Treatment response, Quality of life, Immune system and Intensive care medicine.
His work deals with themes such as Gastroenterology, Expanded Disability Status Scale and Oncology, which intersect with Internal medicine. Mark S. Freedman combines subjects such as Extension study, Protective immunity, Lymphocyte, Physical therapy and Pooled analysis with his study of Teriflunomide. His Placebo research includes elements of Post-hoc analysis, Phases of clinical research and Clinically isolated syndrome.
His primary areas of investigation include Multiple sclerosis, Internal medicine, Clinical trial, Placebo and Hematopoietic stem cell transplantation. He has researched Multiple sclerosis in several fields, including Adverse effect, Disease, Neurology, Pediatrics and Transplantation. The concepts of his Internal medicine study are interwoven with issues in Teriflunomide, Expanded Disability Status Scale, Oncology and Gastroenterology.
His work carried out in the field of Clinical trial brings together such families of science as Pathological, Spinal cord involvement, Myelopathy, Spinal cord and Neuromyelitis Optica Spectrum Disorders. His Placebo research incorporates elements of Clinical endpoint and Phases of clinical research. His Hematopoietic stem cell transplantation study combines topics in areas such as CD58, Immune system and Antibody.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson;Brenda L. Banwell;Frederik Barkhof;Frederik Barkhof;William M. Carroll.
Lancet Neurology (2017)
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter.
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor;Jerry S Wolinsky;Christian Confavreux;Giancarlo Comi.
The New England Journal of Medicine (2011)
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial†
Kathleen Hawker;Paul O'Connor;Mark S. Freedman;Peter A. Calabresi.
Annals of Neurology (2009)
Differential diagnosis of suspected multiple sclerosis: a consensus approach
D. H. Miller;B. G. Weinshenker;M. Filippi;B. L. Banwell.
Multiple Sclerosis Journal (2008)
Quantifying axonal loss after optic neuritis with optical coherence tomography.
Fiona Costello;Stuart Coupland;William Hodge;Gianni R. Lorello.
Annals of Neurology (2006)
Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis
Martin Duddy;Masaaki Niino;Femina Adatia;Sherry Hebert.
Journal of Immunology (2007)
Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis: A Consensus Statement
Mark S. Freedman;Edward J. Thompson;Florian Deisenhammer;Gavin Giovannoni.
JAMA Neurology (2005)
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
Ludwig Kappos;Mark S Freedman;Chris H Polman;Gilles Edan.
The Lancet (2007)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Christian Confavreux;Paul O'Connor;Giancarlo Comi;Mark S. Freedman.
Lancet Neurology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: